Novartis CEO warned U.S. biotech curbs on China could slow drug development
Vas Narasimhan said Treasury's proposed investment limits would hinder moving technologies between U.S. and Chinese operations
We haven't written up this one. Quartz has the full story — the link below goes straight to it.